MedTrace Logo

Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC

NCT06818097 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2025-05-20

No results posted yet for this study

Summary

In China, primary hepatocellular carcinoma (HCC) has high morbidity and mortality, imposing a heavy burden on the public. Surgical resection is an effective treatment, but as HCC is often latent, less than 30% of patients are suitable for surgery at first diagnosis. So systemic anti-tumor therapy is crucial for advanced HCC. Small-molecule targeted drugs like lenvatinib and sorafenib are NCCN-recommended first-line drugs for advanced HCC. The combination of targeted drugs and immune checkpoint inhibitors can prolong overall survival with good safety. The "2024 Guidelines for HCC Diagnosis and Treatment" shows that platinum-containing chemotherapy is a preferred systemic treatment for advanced HCC. However, in real-world practice, the efficacy and safety of the combination of targeted-immunotherapy and chemotherapy regimen for advanced HCC remain unclear.

Conditions

  • Advanced HCC
  • Systemic Therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Efficacy and Safety

Interventions

DRUG

TKI

Lenvatinib

DRUG

anti PD-1

Sintilimab or Camrelizumab or Tislelizumab

DRUG

XELOX chemotherapy

Capecitabine and Oxaliplatin

Sponsors & Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2025-04-01
Completion
2025-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06818097 on ClinicalTrials.gov